论文信息 - The Impact of Pharmacogenomics on the Management of Cardiac Disease - 字舞流文

The Impact of Pharmacogenomics on the Management of Cardiac Disease

R. Weinshilboum | N. Pereira | N. Pereira

[1] R. Weinshilboum,et al. Genomics and drug response. , 2011, The New England journal of medicine.

[2] K. Fagerström,et al. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial , 2010, BMJ : British Medical Journal.

[3] R. Verbrugge,et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). , 2010, Journal of the American College of Cardiology.

[4] E. Antman,et al. Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[5] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[6] P. Tønnesen,et al. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. , 2008, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[7] L. Lazzeroni,et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure , 2006 .

[8] L. Lazzeroni,et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. , 2006, Proceedings of the National Academy of Sciences of the United States of America.